Days af­ter Mer­ck deal, Sutro rolls out $85M E round to fund in­ter­nal can­cer pipeline

7 years ago
Financing

Chi­nese reg­u­la­tors green light Mer­ck­'s Keytru­da in record time; As­traZeneca takes the price-freeze pledge

7 years ago
News Briefing

On top of ex­pir­ing Her­ceptin patents, Roche faces huge roy­al­ty loss­es in 2019

7 years ago
Pharma

As­cle­tis reaps record $400M from Hong Kong in­vestors in the ex­change's first-ever pre-rev­enue biotech list­ing

7 years ago
Financing
China

Now a three-time los­er, selume­tinib con­tin­ues to cause headaches as As­traZeneca dumps a failed PhI­II

7 years ago
R&D

FDA slaps a hold on Sarep­ta's Duchenne MD study in the wake of stel­lar ear­ly re­sults

7 years ago
R&D

Look­ing to mount an R&D turn­around, GSK gets slapped down at the FDA for a weak stab at COPD

7 years ago
Pharma

Ei­sai, Bio­gen bat­tered by con­tro­ver­sy over PhII Alzheimer's study af­ter post­ing pos­i­tive re­sults

7 years ago
R&D

Help want­ed: New CEO to run Gilead as John Mil­li­gan steps down

7 years ago
People

Acor­da shares tank as ap­peals court re­fus­es in­junc­tion against cheap Ampyra knock­offs

7 years ago
Pharma

Pfiz­er plans $465M man­u­fac­tur­ing fa­cil­i­ty at Michi­gan base; Chi­na's Ts­inghua Uni­ver­si­ty inks dis­cov­ery deal with ...

7 years ago
News Briefing

Take­da R&D team rings the block­buster bell with key PhI­II suc­cess in front­line lung can­cer

7 years ago
R&D

Mer­ck claims a need­ed win for Keytru­da with in­ter­im OS da­ta in head and neck can­cer

7 years ago
R&D

With a new HQ un­der con­struc­tion and Ab­b­Vie as a part­ner, Alec­tor grabs $133M round to fund a move in­to the clin­ic

7 years ago
Financing

Months af­ter IPO, No­var­tis spin­out resTOR­bio wins on PhI­Ib da­ta — stock soars

7 years ago
R&D

This is it? GSK rolls out a buzzy new R&D plan long on as­pi­ra­tions and short on per­for­mance goals

7 years ago
Bioregnum
R&D

Za­vante CEO sells his late-stage an­tibi­ot­ic biotech to Nabri­va — grab­bing the helm in the deal

7 years ago
People
Pharma

With moth­ers on erec­tile dys­func­tion drug, 11 new­born ba­bies die af­ter tri­al trig­gers lung prob­lems

7 years ago
R&D

Mer­ck hands Sutro $60M to start on im­munomod­u­la­to­ry drug dis­cov­ery; Eli Lil­ly spin­ning out an­i­mal health group

7 years ago
News Briefing

Bio­gen climbs high­er on Spin­raza sales; inks deal for two new neu­ro­mus­cu­lar drugs

7 years ago
Pharma

API man­u­fac­tur­er Cam­brex buys Ha­lo Phar­ma for $425M — ven­tur­ing in­to fin­ished dose man­u­fac­tur­ing

7 years ago
Deals

Fol­low­ing some clean sweeps in PhI­II, Ab­b­Vie gets an FDA OK on its top-10 block­buster prospect Orilis­sa

7 years ago
Pharma

As Ei­sai, Bio­gen plot a course to ac­cel­er­at­ed ap­provals for Alzheimer’s drug, a mob of skep­tics are wait­ing to ...

7 years ago
R&D
Pharma

Mar­ket slack­er Cel­gene does some­thing good for a change, look­ing to turn the cor­ner on past mishaps

7 years ago
R&D
First page Previous page 1023102410251026102710281029 Next page Last page
A service from the Financial Times